The third episode of this CMEOCast podcast series focuses on best practices for screening for HBV in the ED, incorporating the use of interprofessional teams, and fostering patient education for optimal treatment outcomes.
Dr. Kowdley received his BS in Biology and Anthropology as a member of the Dean’s List at Columbia University, and his medical degree from Mount Sinai School of Medicine. He completed his internship and residency at Oregon Health Science University and a Fellowship in Gastroenterology and Hepatology at Tufts University School of Medicine.
Dr. Kowdley is internationally recognized as a clinician, educator, and researcher in the area of liver disease and has presented his research on liver diseases at more than 165 national and international meetings and scientific symposia. He is the author of over 450 articles, book chapters, reviews, and commentaries in this area, with publications in the Annals of Internal Medicine, Archives of Surgery, Gastroenterology, Hepatology, American Journal of Physiology, and New England Journal of Medicine, among other professional publications.
Dr. Kowdley has extensive experience in clinical trials in all areas of liver disease, including hepatitis C, cholestatic liver disease, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), nonalcoholic steatohepatitis, and hepatitis B. He has been a principal investigator in several NIDDK-sponsored clinical trials in PBC and PSC and is a member of executive committee of the nonalcoholic steatohepatitis clinical research network (NASH CRN). Dr. Kowdley has also served as the lead investigator of several major international clinical trials in hepatitis C.
Dr. Kowdley’s laboratory program is focused on the role of iron as a co-factor in many liver diseases, including hepatitis C, hemochromatosis, and nonalcoholic steatohepatitis (NASH). He has developed murine models for NASH and is currently exploring the contribution of hepatic iron deposition on the severity of NASH.
Dr. Kowdley’s research program has been continuously funded by the NIDDK since 1999 in addition to several grants from foundations and scientific societies.
Carlos Malvestutto, MD, MPH is an Associate Professor of Clinical Medicine in the Division of Infectious Diseases at the Ohio State University Wexner Medical Center. Dr. Malvestutto completed his undergraduate degree at Yale University in New Haven, Connecticut and his master’s in public health at Johns Hopkins University Bloomberg School of Public Health in Baltimore, Maryland. He earned his medical degree from the Ponce Health Sciences University in Ponce, Puerto Rico. He then completed his residency in Internal Medicine at Mount Sinai Hospital in New York, New York and his Infectious Disease Fellowship at New York University Medical Center-Tisch Hospital in New York, New York.
Dr. Malvestutto’s research has focused on cardiovascular complications of HIV as well as HIV cure strategies using broadly neutralizing antibodies. He is a member of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group of the AIDS Clinical Trials Group and serves in the Ending the HIV Epidemic Working Group of the HIV Medical Association.
In the second episode of this CME Outfitters podcast series on EDS, expert faculty will focus on identifying key neurotransmitters involved in the sleep-wake cycle and recognizing how therapies targeted to those key neurotransmitters exert their therapeutic effect on EDS in narcolepsy and OSA.
Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, SC.
Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine, and Pulmonary Diseases.
Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia, and circadian rhythm abnormality.
This CMEOCast podcast features expert faculty focusing on best practices to increase vaccine uptake by engaging and educating patients in pharmacy settings.
Dr. William Schaffner is Professor of Preventive Medicine in the Department of Health Policy and Professor of Infectious Diseases at the Vanderbilt University School of Medicine, Nashville, Tennessee.
Dr. Schaffner’s primary focus has been the prevention of infectious diseases. He is a strong proponent of collaboration between academic medical centers and public health institutions. He has worked extensively on the effective use of vaccines and has been a member of expert advisory committees that establish national vaccine policy.
Dr. Schaffner is committed to the communication of disease prevention with the general public and regards this as a teaching opportunity. He is often invited to comment on communicable disease issues on local and national media, translating research and public health events into language that the public can understand.
After graduating from Yale in 1957, Schaffner attended the University of Freiburg, Germany as a Fulbright Scholar. He graduated from Cornell University Medical College in 1962 and completed residency training and a Fellowship in Infectious Diseases at Vanderbilt. He was commissioned in the U.S. Public Health Service as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention (CDC) for two years. He returned to Vanderbilt after that tour of duty and established a long collaboration with the Tennessee Department of Health and the CDC.
Michael D. Hogue is the current Dean and Professor of Loma Linda University School of Pharmacy, Loma Linda, California. He serves as the 165th president of the American Pharmacists Association (APhA) and is the immediate past Speaker of the House of Delegates of APhA. Throughout his career, Dr. Hogue has served many different roles in pharmacy practice, including owning an independent community pharmacy and home infusion company, working in a chain community pharmacy, and later as an ambulatory care pharmacist in family practice medicine.
Dr. Hogue was on the staff development team and an original national faculty member for APhA’s Pharmacy-Based Immunization Delivery national certificate program for pharmacists, which over 350,000 pharmacists and student pharmacists have completed since its inception in 1996. He continues to be actively engaged in immunization policy and advocacy in pharmacy, as well as education of nurse practitioners and physicians in disease prevention through vaccines. He has conducted several studies in the area of vaccine implementation through pharmacies, written dozens of manuscripts and monographs related to vaccines and vaccine preventable diseases and speaks frequently around the globe on the subject. Dr. Hogue was the first pharmacist in the state of Alabama to administer vaccines in his pharmacy practice in 1997.
Dr. Hogue holds a Bachelor’s in Pharmacy and a PharmD degree from Samford University, Birmingham, Alabama. As a student, he became very involved in the pharmacist recovery network movement and served as the editor and author on a book to assist schools and colleges of pharmacy in dealing with drug and alcohol abuse within the profession. As a practitioner and later as president of APhA’s Academy of Pharmacy Practice and Management, Hogue led or served on several sentinel groups to move the recognition of pharmacists forward, including the Pharmacy Services Technical Advisory Committee (PSTAC) to the American Medical Association, and the consensus group which was assigned with the responsibility of defining Medication Therapy Management Services. He subsequently published with APhA the profession’s first two books on payment for pharmacist’s non-dispensing services.
This CME Outfitters Live and OnDemand webcast will focus on the burden imposed by shingles, improving uptake of vaccination and series completion for shingles through patient education, and applying real-world strategies to implement shingles immunization protocols.
Dr. William Schaffner is Professor of Preventive Medicine in the Department of Health Policy and Professor of Infectious Diseases at the Vanderbilt University School of Medicine, Nashville, Tennessee.
Dr. Schaffner’s primary focus has been the prevention of infectious diseases. He is a strong proponent of collaboration between academic medical centers and public health institutions. He has worked extensively on the effective use of vaccines and has been a member of expert advisory committees that establish national vaccine policy.
Dr. Schaffner is committed to the communication of disease prevention with the general public and regards this as a teaching opportunity. He is often invited to comment on communicable disease issues on local and national media, translating research and public health events into language that the public can understand.
After graduating from Yale in 1957, Schaffner attended the University of Freiburg, Germany as a Fulbright Scholar. He graduated from Cornell University Medical College in 1962 and completed residency training and a Fellowship in Infectious Diseases at Vanderbilt. He was commissioned in the U.S. Public Health Service as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention (CDC) for two years. He returned to Vanderbilt after that tour of duty and established a long collaboration with the Tennessee Department of Health and the CDC.
Professor Anthony (Tony) Cunningham, AO, MD, MBBS stepped down as Executive Director of The Westmead Institute for Medical Research after 23 years (1996 – 2019) and now continues as Director of the Institute’s Centre for Virus Research and Professor, Faculty of Medicine and Health in the University of Sydney. He is also Director of the Australian Centre for HIV and Hepatitis Virology Research (ACH2), which is funded directly by the Australian Government, as well as the NSW/ACT State Branch Chair, The Australian Academy of Health and Medical Sciences.
He is a clinician scientist who trained in infectious diseases and virology research at the University of Melbourne and as a postdoctoral fellow in infectious diseases at Stanford University. His longstanding research is in herpes virus and HIV immunology relevant to vaccine development, culminating in lead international roles in the pivotal trials of a vaccine candidate for herpes simplex and a highly efficacious vaccine for Herpes zoster. He has published extensively in most aspects of immunization for herpes zoster and more broadly on immunization in general. He is currently investigating the mechanism of action of adjuvants to counteract declining immunity and vaccine efficacy in the ageing.
Iris Gorfinkel, MD, CM, is a family physician and Founder/Principal Investigator of PrimeHealth Clinical Research. She has participated in over 60 clinical trials and has a special interest in vaccination research. She helped co-author seminal papers on Shingrix and sat as a co-chair on the Shingrix Advisory Board. Additionally, Dr. Gorfinkel is active in-patient advocacy and produces a regular medical radio column on CBC Radio One.
This CME Outfitters podcast episode aims to provide learners with strategies to provide culturally appropriate counseling and support services to high-risk populations in order to optimize retention and long-term HBV care.
Dr. Kowdley received his BS in Biology and Anthropology as a member of the Dean’s List at Columbia University, and his medical degree from Mount Sinai School of Medicine. He completed his internship and residency at Oregon Health Science University and a Fellowship in Gastroenterology and Hepatology at Tufts University School of Medicine.
Dr. Kowdley is internationally recognized as a clinician, educator, and researcher in the area of liver disease and has presented his research on liver diseases at more than 165 national and international meetings and scientific symposia. He is the author of over 450 articles, book chapters, reviews, and commentaries in this area, with publications in the Annals of Internal Medicine, Archives of Surgery, Gastroenterology, Hepatology, American Journal of Physiology, and New England Journal of Medicine, among other professional publications.
Dr. Kowdley has extensive experience in clinical trials in all areas of liver disease, including hepatitis C, cholestatic liver disease, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), nonalcoholic steatohepatitis, and hepatitis B. He has been a principal investigator in several NIDDK-sponsored clinical trials in PBC and PSC and is a member of executive committee of the nonalcoholic steatohepatitis clinical research network (NASH CRN). Dr. Kowdley has also served as the lead investigator of several major international clinical trials in hepatitis C.
Dr. Kowdley’s laboratory program is focused on the role of iron as a co-factor in many liver diseases, including hepatitis C, hemochromatosis, and nonalcoholic steatohepatitis (NASH). He has developed murine models for NASH and is currently exploring the contribution of hepatic iron deposition on the severity of NASH.
Dr. Kowdley’s research program has been continuously funded by the NIDDK since 1999 in addition to several grants from foundations and scientific societies.
Dr. Martinez cares for patients with liver disease and addiction disorders, including opiate dependency, viral hepatitis, alcoholic and fatty liver disease, at Erie County Medical Center where he is the Medical Director of Hepatology. His clinic “La Bodega” has been recognized both nationally and internationally as a novel co- localized model for the management of viral hepatitis and addiction disorders, and has been awarded a New York State World AIDS Day Commissioner’s Special Recognition Award. The clinic has also been designated as a center for drug user health in New York State. Dr. Martinez has lectured around the world on hepatitis C management among people with substance use disorders, most recently at the International Hepatology Exchange in Amsterdam. His team’s work has been presented at the annual liver meeting of the American Association for the Study of Liver Diseases (AASLD); the annual conference of the International Network On Viral Hepatitis in Substance Users, and at the International Liver Congress.
His research involves improving hepatitis C treatment in populations disproportionately affected by HCV, particularly people who inject drugs. He has been a primary and co-investigator on numerous clinical trials related to new therapeutic agents for hepatitis C and fatty liver disease.
A fierce advocate, he has worked to eliminate hepatitis C treatment restrictions throughout the United States and in Europe.
Dr. Martinez is a member of the AASLD where he was recently elected to the HCV special interest group steering committee, the European Association for the Study of the Liver, and the American Society of Addiction Medicine.
The first episode of this CMEOCast podcast series focuses on reinforcing the importance of vaccination against shingles, improving vaccination uptake in ethnic minorities and at-risk patients, and developing best practices to implement a shingles protocol in primary care settings.
Dr. William Schaffner is Professor of Preventive Medicine in the Department of Health Policy and Professor of Infectious Diseases at the Vanderbilt University School of Medicine, Nashville, Tennessee.
Dr. Schaffner’s primary focus has been the prevention of infectious diseases. He is a strong proponent of collaboration between academic medical centers and public health institutions. He has worked extensively on the effective use of vaccines and has been a member of expert advisory committees that establish national vaccine policy.
Dr. Schaffner is committed to the communication of disease prevention with the general public and regards this as a teaching opportunity. He is often invited to comment on communicable disease issues on local and national media, translating research and public health events into language that the public can understand.
After graduating from Yale in 1957, Schaffner attended the University of Freiburg, Germany as a Fulbright Scholar. He graduated from Cornell University Medical College in 1962 and completed residency training and a Fellowship in Infectious Diseases at Vanderbilt. He was commissioned in the U.S. Public Health Service as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention (CDC) for two years. He returned to Vanderbilt after that tour of duty and established a long collaboration with the Tennessee Department of Health and the CDC.
Iris Gorfinkel, MD, CM, is a family physician and Founder/Principal Investigator of PrimeHealth Clinical Research. She has participated in over 60 clinical trials and has a special interest in vaccination research. She helped co-author seminal papers on Shingrix and sat as a co-chair on the Shingrix Advisory Board. Additionally, Dr. Gorfinkel is active in-patient advocacy and produces a regular medical radio column on CBC Radio One.